Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/714| Title: | Pharmacotherapeutics of SARS-CoV-2 Infections |
| Authors: | Kevadiya, B D Machhi, J Herskovitz, J et al. |
| Keywords: | SARS-CoV-2 COVID-19 therapeutics |
| Issue Date: | 2021 |
| Publisher: | Journal of Neuroimmune Pharmacology, 16 (Springer) |
| Series/Report no.: | ;12-37 |
| Abstract: | The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. |
| URI: | https://link.springer.com/article/10.1007/s11481-020-09968-x http://localhost:8080/xmlui/handle/123456789/714 |
| ISSN: | 1557-1904 |
| Appears in Collections: | Research Papers |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Book Info.docx | 9.83 kB | Microsoft Word XML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.